The long-term outlook for CRISPR Therapeutics (CRSP) is anchored by its transition from a pure research-stage biotech venture into a commercial-stage biopharmaceutical leader. Continued revenue expansion from Casgevy, coupled with successful clinical trials for in vivo gene-editing candidates targeting cardiovascular and genetic diseases, provides a strong fundamental thesis, though high market volatility and regulatory hurdles remain key factors.